XenoGesis Ltd is a laboratory-based contract research organisation specialising in preclinical drug metabolism and pharmacokinetics, quantitative bioanalysis and expert intpretation. Based in Nottingham’s BioCity, XenoGesis was established in June 2011 by Richard Weaver. Spotting a real gap in the market in this sector, Richard set up XenoGesis following the announced closure of AstraZeneca Charnwood and has subsequently created a number of employment opportunities for former AZ employees.
V Formation has worked with XenoGesis from the early stages to help the organisation build its profile within the industry. The focus now is to build that profile on a global basis.
In its first year XenoGesis secured an encouraging number of clients and collaboration agreements and in May 2012, XenoGesis won the Start Up Award at the Medilink East Midlands Innovation Day Awards in recognition of their early successes. The company has now grown to 14 employees and taken on more space within BioCity. The proactive marketing programme has taken XenoGesis on market visits across Europe bringing more work back into the UK.
XenoGesis prides itself on its consultative approach to DMPK and research projects. To find out more about the XenoGesis story, have a look at their recent video.View all projects